What North Carolina Patients Should Know About Ozempic and Gastroparesis

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Risk Awareness

If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering if the medication could be causing gastroparesis—a condition where the stomach empties too slowly. The longstanding tradition of providing clear, accessible health information helps patients navigate emerging concerns like this one. This page offers straightforward facts about the link between Ozempic and gastroparesis, tailored for North Carolina readers.

Understanding Ozempic and Its Gastrointestinal Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Clinical data from placebo-controlled trials demonstrate a significantly higher rate of gastrointestinal adverse reactions among patients receiving Ozempic compared to placebo. In these trials, gastrointestinal adverse reactions occurred in 32.7% of patients on Ozempic 0.5 mg and 36.4% on Ozempic 1 mg, versus 15.3% on placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and diarrhea occurred during dose escalation, and discontinuation due to gastrointestinal adverse reactions was higher in the Ozempic groups (3.1% for 0.5 mg, 3.8% for 1 mg) compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions reported at frequencies below 5% include dyspepsia (3.5% for 0.5 mg, 2.7% for 1 mg), gastroesophageal reflux disease (1.9% for 0.5 mg, 1.5% for 1 mg), and gastritis (0.8% for both doses) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

The Link Between Ozempic and Gastroparesis

Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, presenting with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. The clinical presentation of gastroparesis overlaps with the gastrointestinal adverse effects commonly reported with Ozempic, including nausea, vomiting, dyspepsia, and gastroesophageal reflux disease. Mechanistically, GLP-1 receptor agonists like Ozempic slow gastric emptying through activation of GLP-1 receptors on vagal afferent neurons and enteric neurons, leading to reduced antral contractions and increased pyloric tone. This pharmacodynamic effect is integral to the drug's glucose-lowering action but can become pathological in susceptible individuals, potentially precipitating or exacerbating gastroparesis. Postmarketing reports have highlighted rare cases of pulmonary aspiration in patients undergoing elective surgeries or procedures requiring general anesthesia or deep sedation, attributed to retained gastric contents despite adherence to preoperative fasting recommendations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This underscores the clinical significance of delayed gastric emptying associated with GLP-1 receptor agonists. The adequacy of warnings regarding the risk of gastroparesis with Ozempic is a critical consideration. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and the potential for retained gastric contents during anesthesia, but does not explicitly list gastroparesis as a specific adverse reaction. The label notes that available data are insufficient to inform recommendations for mitigating the risk of pulmonary aspiration, including whether modifying preoperative fasting or temporarily discontinuing the drug could reduce the incidence of retained gastric contents (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98). This lack of specific guidance may leave patients and healthcare providers unaware of the potential for gastroparesis as a distinct clinical entity, rather than a transient side effect.

Statute of Limitations for Ozempic Claims in North Carolina

For affected patients in North Carolina, attorney-related considerations involve the statute of limitations for filing a product liability claim. In North Carolina, the statute of limitations for personal injury claims, including those related to defective drugs, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered, through due diligence. The timeline between exposure to Ozempic and documented harm is crucial for establishing when the statute begins to run. Patients who develop symptoms of gastroparesis—such as persistent nausea, vomiting, or abdominal pain—during or after Ozempic use should document the onset of symptoms and any medical diagnoses. The harm may be recognized only after diagnostic testing, such as gastric emptying scintigraphy, confirms delayed gastric emptying. This diagnostic confirmation may occur months or years after initial exposure, potentially affecting the statute of limitations calculation. Given the mechanistic link between Ozempic and delayed gastric emptying, patients experiencing persistent gastrointestinal symptoms should seek medical evaluation for gastroparesis. Legal counsel can assess whether the manufacturer provided adequate warnings about this risk and whether the patient's harm falls within the applicable statute of limitations. The evidence from clinical trials and postmarketing reports supports a plausible association between Ozempic and gastroparesis, but individual cases require careful review of the timing and nature of symptoms.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic-related gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including product liability claims related to defective drugs, is generally three years from the date of injury or from when the injury was discovered, or reasonably should have been discovered, through due diligence. For Ozempic-related gastroparesis, the clock may start when symptoms are diagnosed via tests like gastric emptying scintigraphy.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) slows gastric emptying by activating GLP-1 receptors on vagal afferent and enteric neurons, reducing antral contractions and increasing pyloric tone. While this effect helps control blood sugar, it can become pathological in some individuals, leading to or exacerbating gastroparesis, a condition of delayed gastric emptying without mechanical obstruction.

What gastrointestinal side effects are common with Ozempic?

Clinical trials show gastrointestinal adverse reactions occur in 32.7% of patients on Ozempic 0.5 mg and 36.4% on 1 mg, compared to 15.3% on placebo. Common effects include nausea, vomiting, diarrhea, dyspepsia (3.5% and 2.7%), gastroesophageal reflux disease (1.9% and 1.5%), and gastritis (0.8% for both doses) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.